Defence Therapeutics Inc. (CSE:DTC)
Canada flag Canada · Delayed Price · Currency is CAD
0.7700
0.00 (0.00%)
Oct 31, 2025, 1:02 PM EDT

Defence Therapeutics Income Statement

Millions CAD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 20212019 - 2020
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21 2019 - 2020
Selling, General & Admin
1.522.962.63.141.06
Upgrade
Research & Development
0.83.863.583.761.16
Upgrade
Amortization of Goodwill & Intangibles
-0.040.01--
Upgrade
Operating Expenses
3.1912.756.497.272.83
Upgrade
Operating Income
-3.19-12.75-6.49-7.27-2.83
Upgrade
Interest Expense
-0.32-0.4-0.26--
Upgrade
Interest & Investment Income
00.020.01--
Upgrade
Currency Exchange Gain (Loss)
-0.010-0.07-0.02-
Upgrade
Other Non Operating Income (Expenses)
-0.08-0.08-0.05-0.05-0.03
Upgrade
EBT Excluding Unusual Items
-3.6-13.19-6.87-7.34-2.86
Upgrade
Other Unusual Items
0.08----
Upgrade
Pretax Income
-3.52-13.19-6.87-7.34-2.86
Upgrade
Income Tax Expense
---0.11--
Upgrade
Net Income
-3.52-13.19-6.76-7.34-2.86
Upgrade
Net Income to Common
-3.52-13.19-6.76-7.34-2.86
Upgrade
Shares Outstanding (Basic)
5045403627
Upgrade
Shares Outstanding (Diluted)
5045403627
Upgrade
Shares Change (YoY)
11.64%12.54%9.93%35.65%2719.76%
Upgrade
EPS (Basic)
-0.07-0.30-0.17-0.20-0.11
Upgrade
EPS (Diluted)
-0.07-0.30-0.17-0.20-0.11
Upgrade
Free Cash Flow
-3.4-4.49-7.72-6.04-2.29
Upgrade
Free Cash Flow Per Share
-0.07-0.10-0.20-0.17-0.09
Upgrade
EBITDA
-3.12-12.68-6.48--
Upgrade
D&A For EBITDA
0.070.070.01--
Upgrade
EBIT
-3.19-12.75-6.49-7.27-2.83
Upgrade
Advertising Expenses
0.531.711.962.52-
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.